CARDIOMETRICS' FLOWIRE/FLOMAP SALES SURGE 70% TO $8.5 MIL.
This article was originally published in The Gray Sheet
Executive SummaryCARDIOMETRICS' FLOWIRE/FLOMAP SALES SURGE 70% TO $8.5 MIL. in 1993, company President and CEO Menahem Nassi told investors Jan. 10 at the Hambrecht & Quist life sciences conference in San Francisco. The two products provided all the privately held Mountain View, California-based firm's revenues during the year; 60% of the sales were from overseas markets. FloWire and FloMap generated $1 mil. in sales in the half year they were available in 1991.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.